Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma ... and 25% to 30% of them develop nasal polyps as a result. Sanofi and Regeneron have said that ...

Fasenra is approved for treating severe eosinophilic asthma. AZN is also evaluating Fasenra in late-stage studies for ...

Monoclonal antibody therapies or biological therapies have been developed to alter the immune response in eosinophilic asthma and nasal polyps. Biologic therapies have been shown to reduce asthma ...

blood eosinophil count [BEC], exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide [FeNO] level and presence of atopy and chronic rhinosinusitis with nasal polyps.” ...

Sanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP ... syndrome (HES) and eosinophilic granulomatosis with polyangiitis ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

“The take-home message is that nasal transcriptomic profiling may effectively identify asthma endotypes in youth, providing insights beyond traditional biomarkers like IgE or eosinophils ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...